Close Menu
Home › NeoGenomic Redeems Series A Redeemable Preferred Stock for $50.1M

NeoGenomic Redeems Series A Redeemable Preferred Stock for $50.1M

Jun 25, 2018
|
staff reporter

NEW YORK (GenomeWeb) – NeoGenomics announced after the close of the market on Monday that it has redeemed 6,864,000 million shares of Series A Redeemable Preferred Stock held by an affiliate of General Electric Company for approximately $50.1 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Featured Webinar

Development of a Novel Multiplex Assay: A Partnership Case Study

Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.

What's Popular?

In Clinical Lab Management

  1. JP Morgan Healthcare Day 2: Abbott, Caris, Danaher, Quest, LabCorp, Luminex, Agilent, Adaptive Bio

  2. Lab Owner in $130M Genetic Testing Fraud Case Pleads Guilty

  3. SpeeDx, LabCorp Will Codevelop MDx Tests

  4. AACC Issues Guidance on Biotin Interference in Lab Tests

  5. Siemens Healthineers to Distribute ARK Diagnostics Fentanyl Assay

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.